NEW YORK, Sept. 21, 2023 /PRNewswire/ — Transcend Therapeutics, the visionary biotech on a mission to revolutionize neuropsychiatric treatments, proudly announces a transformative partnership with Yale University.
Together, they’ve clinched a game-changing $1 million grant from the U.S. Department of Defense, embarking on pioneering preclinical research focused on methylone—Transcend’s leading candidate for conquering post-traumatic stress disorder (PTSD). This research, leveraging cutting-edge microscopy and behavioral methods, is set to unveil the mysterious neurobiological magic behind methylone’s rapid and enduring therapeutic impact on PTSD.
Transcend’s Co-Founder and CEO, Blake Mandell, emphasizes the potential locked within methylone: “We’ve seen glimpses of its potential in clinical cases and ongoing research. Yale’s groundbreaking investigation, backed by the Department of Defense, promises invaluable insights into the brain’s remarkable neuroplastic response to methylone.”
But the excitement doesn’t end there. Transcend is already in the trenches with IMPACT-1, a clinical trial underway in the United Kingdom, scrutinizing the safety and efficacy of methylone in individuals grappling with severe PTSD. Anticipation is high, with the open-label Part A results expected to shine by the close of 2023. After that, it’s onto Part B—a randomized, double-blind, placebo-controlled exploration of methylone’s prowess with up to 64 PTSD patients.
Dr. Ben Kelmendi, Transcend’s Co-Founder and Chief Scientific Advisor, leaves no room for doubt about the urgency of their mission: “The demand, especially among our veterans, for breakthrough PTSD treatments is immense.” Dr. Kelmendi, a leading figure at the U.S. Department of Veterans Affairs National Center for PTSD and co-director of the Yale Program for Psychedelic Science, knows firsthand the pressing need for progress in this realm.
Founded in 2021, Transcend Therapeutics is driving innovation in neuroscience, offering hope to those left disillusioned by current psychiatric medications. Their flagship candidate, methylone—a rapid-acting neuroplastogen—is currently at the heart of a Phase 2 study for PTSD. With a leadership team that boasts 13 FDA approvals and a role in $7 billion worth of M&A and public company value, Transcend is not just a corporation; it’s a Public Benefit Corporation, devoted to channeling 10% of its founding shares toward nonprofit organizations advancing scientific research and patient access.